FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016393433> ?p ?o ?g. }

• W2016393433 endingPage "2867" @default.
• W2016393433 startingPage "2856" @default.
• W2016393433 abstract "The authors previously have found that in patients with locally advanced squamous cell carcinoma of the head and neck (SCC-HN), alternating chemoradiotherapy (ALT) was superior to low-total-dose conventional radiotherapy alone. The purpose of this randomized trial was to compare the same chemoradiotherapy approach with high-total-dose partly accelerated radiotherapy.During 6 years, 136 consecutive patients with previously untreated unfavorable Stage II or Stage III-IV (International Union Against Cancer) SCC of the oral cavity, pharynx, and larynx were enrolled. They were randomly assigned to chemotherapy consisting of 4 cycles of intravenous cisplatin (20 mg/m(2) of body surface area per day for 5 consecutive days) and 5-fluorouracil (200 mg/m(2) per day for 5 consecutive days; weeks 1, 4, 7, and 10) alternated with three 2-week courses of radiotherapy (20 grays [Gy] per course, 2 Gy per day, 5 days per week; ALT, 70 patients) or to partly accelerated radiotherapy with final concomitant boost technique (75 Gy/40 fractions in 6 weeks; partly accelerated radiotherapy [PA-RT], 66 patients).At the median follow-up of 60 months (range, 30-102 months), no statistical differences were observed in overall survival, progression free survival, or locoregional control between the 2 treatments. Actuarial 3-year overall survival and progression free survival were 37% and 35%, respectively, in the ALT group and 29% and 27%, respectively, in PA-RT group. The median overall survival and progression free survival were 24 and 15 months, respectively, in the ALT arm and 18 and 11 months, respectively, in PA-RT arm. Actuarial 3-year locoregional control rates were 32% in the ALT group and 27% in the PA-RT group. At multivariate analysis, tumor classification was the only factor that emerged as a significant independent variable affecting overall survival. Patients treated in the PA-RT arm experienced higher Grade 3+ (World Health Organization) acute skin and mucosal reactions than patients in the ALT arm. Moreover, local late mucosal and skin toxicities occurred more often in patients treated with PA-RT.This trial failed to disclose statistically significant differences in the outcome of patients treated with either ALT or PA-RT. Therefore, definitive conclusions could not be made. However, acute skin effects and late mucosal and skin toxicities above the clavicles appeared to be significantly lower with chemoradiotherapy." @default.
• W2016393433 created "2016-06-24" @default.
• W2016393433 creator A5004091943 @default.
• W2016393433 creator A5015046932 @default.
• W2016393433 creator A5032802941 @default.
• W2016393433 creator A5057809323 @default.
• W2016393433 creator A5062442517 @default.
• W2016393433 creator A5076610275 @default.
• W2016393433 creator A5082648526 @default.
• W2016393433 creator A5084468947 @default.
• W2016393433 creator A5084634836 @default.
• W2016393433 creator A5088956472 @default.
• W2016393433 date "2001-01-01" @default.
• W2016393433 modified "2023-10-16" @default.
• W2016393433 title "Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck" @default.
• W2016393433 cites W1759456481 @default.
• W2016393433 cites W1784479792 @default.
• W2016393433 cites W1807514388 @default.
• W2016393433 cites W1921758320 @default.
• W2016393433 cites W1968741994 @default.
• W2016393433 cites W1974114705 @default.
• W2016393433 cites W1985219235 @default.
• W2016393433 cites W1993093499 @default.
• W2016393433 cites W1998694433 @default.
• W2016393433 cites W2026132872 @default.
• W2016393433 cites W2046650471 @default.
• W2016393433 cites W2063034912 @default.
• W2016393433 cites W2085409346 @default.
• W2016393433 cites W2104854477 @default.
• W2016393433 cites W2119849411 @default.
• W2016393433 cites W2139554459 @default.
• W2016393433 cites W2151415400 @default.
• W2016393433 cites W2151616125 @default.
• W2016393433 cites W2152609192 @default.
• W2016393433 cites W2167805334 @default.
• W2016393433 cites W2321681371 @default.
• W2016393433 cites W2331395194 @default.
• W2016393433 cites W2406213538 @default.
• W2016393433 cites W2408805009 @default.
• W2016393433 cites W4205151458 @default.
• W2016393433 cites W4254435116 @default.
• W2016393433 cites W4293241248 @default.
• W2016393433 cites W2091637192 @default.
• W2016393433 doi "https://doi.org/10.1002/1097-0142(20011201)92:11<2856::aid-cncr10132>3.0.co;2-6" @default.
• W2016393433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11753959" @default.
• W2016393433 hasPublicationYear "2001" @default.
• W2016393433 type Work @default.
• W2016393433 sameAs 2016393433 @default.
• W2016393433 citedByCount "51" @default.
• W2016393433 countsByYear W20163934332012 @default.
• W2016393433 countsByYear W20163934332013 @default.
• W2016393433 countsByYear W20163934332014 @default.
• W2016393433 countsByYear W20163934332015 @default.
• W2016393433 countsByYear W20163934332016 @default.
• W2016393433 countsByYear W20163934332017 @default.
• W2016393433 countsByYear W20163934332018 @default.
• W2016393433 countsByYear W20163934332021 @default.
• W2016393433 countsByYear W20163934332022 @default.
• W2016393433 countsByYear W20163934332023 @default.
• W2016393433 crossrefType "journal-article" @default.
• W2016393433 hasAuthorship W2016393433A5004091943 @default.
• W2016393433 hasAuthorship W2016393433A5015046932 @default.
• W2016393433 hasAuthorship W2016393433A5032802941 @default.
• W2016393433 hasAuthorship W2016393433A5057809323 @default.
• W2016393433 hasAuthorship W2016393433A5062442517 @default.
• W2016393433 hasAuthorship W2016393433A5076610275 @default.
• W2016393433 hasAuthorship W2016393433A5082648526 @default.
• W2016393433 hasAuthorship W2016393433A5084468947 @default.
• W2016393433 hasAuthorship W2016393433A5084634836 @default.
• W2016393433 hasAuthorship W2016393433A5088956472 @default.
• W2016393433 hasBestOaLocation W20163934331 @default.
• W2016393433 hasConcept C126322002 @default.
• W2016393433 hasConcept C126894567 @default.
• W2016393433 hasConcept C141071460 @default.
• W2016393433 hasConcept C146357865 @default.
• W2016393433 hasConcept C151730666 @default.
• W2016393433 hasConcept C2776283816 @default.
• W2016393433 hasConcept C2776530083 @default.
• W2016393433 hasConcept C2776694085 @default.
• W2016393433 hasConcept C2777546739 @default.
• W2016393433 hasConcept C2778424827 @default.
• W2016393433 hasConcept C2779384505 @default.
• W2016393433 hasConcept C2780474809 @default.
• W2016393433 hasConcept C509974204 @default.
• W2016393433 hasConcept C71924100 @default.
• W2016393433 hasConcept C86803240 @default.
• W2016393433 hasConceptScore W2016393433C126322002 @default.
• W2016393433 hasConceptScore W2016393433C126894567 @default.
• W2016393433 hasConceptScore W2016393433C141071460 @default.
• W2016393433 hasConceptScore W2016393433C146357865 @default.
• W2016393433 hasConceptScore W2016393433C151730666 @default.
• W2016393433 hasConceptScore W2016393433C2776283816 @default.
• W2016393433 hasConceptScore W2016393433C2776530083 @default.
• W2016393433 hasConceptScore W2016393433C2776694085 @default.
• W2016393433 hasConceptScore W2016393433C2777546739 @default.
• W2016393433 hasConceptScore W2016393433C2778424827 @default.
• W2016393433 hasConceptScore W2016393433C2779384505 @default.
• W2016393433 hasConceptScore W2016393433C2780474809 @default.

• next